A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

International Clinical Psychopharmacology

Volumn 17, Issue 6, 2002, Pages 297-305

  Wilcock, G ^a   Möbius, Hans Jörg ^a   Stoffler A ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

ADAS cog; Cognition; Memantine; NMDA receptor antagonist; Randomized controlled trial; Vascular dementia

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AGED; AGITATION; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN PROTECTION; BRONCHITIS; CATARACT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FALLING; FEMALE; GAIT DISORDER; HEADACHE; HUMAN; INJURY; INSOMNIA; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNITED KINGDOM; URINE INCONTINENCE; VERTIGO;

EID: 0036840767     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200211000-00005     Document Type: Article

References (31)

1. Amar K, Wilcock G (1996) Vascular dementia - Fortnightly review. BMJ 312:227-231.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R, 3rd Rev. Edn. Washington, DC: American Psychiatric Association, pp. 103-123.
3. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565-571.
4. Bauer P, Köhne K (1994) Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029-1041.
5. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP (1992) Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 40:237-244.
6. Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H, Hachinski VC (1997) Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol 54:697-703.
7. Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14:3-47.
8. Committee for Proprietary Medicinal Products (CPMP) (1997) Note for Guidance on Medicinal Products in the Treatment of Atzheimer's Disease, CPMP/EWP/553/95. London: The European Agency for the Evaluation of Medicinal Products.
9. Danysz W, Parsons CG, Möbius HJ, Stöffier A, Quack G (2000) Neuroprotective and symptomalogical action of memantine relevant for Alzheimer's disease - A unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2:85-98.
10. Ferris S (1999) Cognitive outcome measures. Alzheimer Dis Assoc Disord 13:S140-S142.
11. Folstein MF, Folstein SE, McHugh PR (1975) 'MiniMental State'. A practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 12:189-198.
12. Forette F, Amery A, Staessen J, Strasser T, Thijs L, Beevers DG, et al. (1991) Is prevention of vascular dementia possible? The Syst-Eur Vascular Dementia Project. Aging 3:373-382.
13. Gottfries CG, Bråne G, Gullberg B, Steen G (1982) A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1:311-330.
14. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988) Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 12:421-430.
15. Hachinski V (1994) Vascular dementia: A radical redefinition. Dementia 5:130-132.
16. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
17. Kittner B, Rossner M, Rother M (1997) Clinical trials in dementia with propentofylline. Ann NY Acad Sci 826:307-316.
18. Möbius HJ (1999) Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 13:172-178.
19. Mohs RC, Cohen L (1988) Alzheimer's disease Assessment Scale (ADAS), Psychopharmacol Bull 24:627-628.
20. National Institute of Mental Health (1976) CGI. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, Revised Edn (Guy W, ed.), Rockville, MD: National Institute of Mental Health. pp. 217-222.
21. Orgogozo JM, Rigaud A-S, Stöffler A, Mobius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 33:1834-1839.
22. Pantoni L, Leys D, Fazekas F, Longstreth WT, Inzitari D, Wallin A, et al. (1999) Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 13:S49-S54.
23. Reisberg B, Windscheif U, Ferris SH, Hingorani VN, Stöffler A, Möbius HJ (2000) Memantine in moderately severe to severe Alzheimeŕs disease (AD): Results of a placebo-controlled 6-month trial. Neurobiol Aging 21:275.
24. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260.
25. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Annal Neurol 7:486-488.
26. Spiegel R, Brunner C, Ermini-Fuenfschilling D, Monsch A, Notter M, Puxty J (1991) A new behavioural assessment scale for geriatric out- and in-patients: The NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 39:339-347.
27. Wilcock G (2000) Cognitive improvement by memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 trial). The 6th International Springfield Symposium on Advances in Alzheimer Therapy, Stockholm.
28. Wilcock G, Stöffler A, Sahin K, Möbius HJ (2000) Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur Neuropsychopharmacol 10:S360.
29. Winblad B, Poritis N (1999) Memantine in severe dementia: Results of the M-Best study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14:135-146.
30. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama study. Neurology 45:1161-1168.
31. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296:239-246.